Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma

NCT03092856 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03092856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03092856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 19, 2017
Completion date
December 31, 2027
Enrollment
62 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, metastatic renal cell cancer, recurrent renal cell carcinoma, stage iv renal cell cancer